The ARIES trial compares an early versus a late start for a treat-and-extend (T&E) regimen, an increasingly popular approach to treatment worldwide, for wet or neovascular age-related macular degeneration (AMD). Professor Paul Mitchell gives an overview of the study, and discusses wet AMD and the differences to dry AMD, the specifics and benefits of the T&E regimen and the importance of dosing frequency in real-world cases.
1. Could you please summarise the study design, rationale and aims of the ongoing ARIES clinical trial? What is unique with the ARIES study? (0:11)
2. What is wet age-related macular degeneration (also known as neovascular AMD), and how does it differ in pathogenesis and manifestation from dry AMD? (1:46)
3. What is aflibercept, and how does it differ from other anti-VEGF drugs? (2:42)
4. How does the treat-and-extend (T&E) regimen differ from a monthly treatment regimen? Are there any benefits of T&E compared with monthly treatment? (3:20)
5. How important is the dosing frequency for real-world AMD treatment from the point of view of both patients and clinicians? (4:11)
Speaker disclosures: Paul Mitchell is a speaker for Bayer.
Filmed at the American Academy of Ophthalmology (AAO) 2018 Annual Meeting, Chicago, IL, US, 27–30 October 2018.
Share this Video
Related Videos In Retina/Vitreous
Sunir Garg, Hawaiian Eye 2022: Mask Use and Endophthalmitis
Universal mask use was shown to be effective at reducing incidence of endophthalmitis, according to results of a study presented at Hawaiian Eye 2022. We caught up with Dr Sunir Garg (Retina Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, USA), who gave us an overview of his retrospective review on mask use and […]
Sunir Garg, Hawaiian Eye 2022: Intravitreal Injections and Endophthalmitis
Universal mask use was shown to be effective at reducing incidence of endophthalmitis, according to results of a study presented at Hawaiian Eye 2022. We had the honour of interviewing Dr Sunir Garg (Retina Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, USA) about his talk on the causes of endophthalmitis and its relationship […]
J Fernando Arevalo, AAO 2021: Highlights and Future Perspectives
We were honored to have the opportunity to ask J Fernando Arevalo (Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA) about his highlights from the American Academy of Ophthalmology Virtual Meeting 2021. Speaker Disclosure: J Fernando Arevalo has received consultant and advisor fees from Abbvie, Genentech and Thea Laboratories, patents/royalty from […]
Journal articles and more to your inbox
Get the latest clinical insights from touchOPHTHALMOLOGYSign me up!